Loading clinical trials...
Loading clinical trials...
Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants With Moderately Severe to Severe Hemophilia A(FVIII:C≤1%)
Conditions
Interventions
PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy
Locations
36
United States
NOW Physical Therapy
Mountain View, California, United States
Clinical and Translational Research Unit (CTRU)
Palo Alto, California, United States
Lucile Packard Childrens Hospital
Palo Alto, California, United States
Imaging Clinic at Stanford Medicine Outpatient Center in Redwood City
Redwood City, California, United States
UCSF IDS Pharmacy
San Francisco, California, United States
University of California, San Francisco - Clinical Research Center
San Francisco, California, United States
Start Date
August 18, 2020
Primary Completion Date
June 17, 2024
Completion Date
October 25, 2028
Last Updated
August 17, 2025
NCT06820515
NCT07226206
NCT05987449
NCT04563520
NCT04645199
NCT06833983
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions